---
title: "Concord Drugs Ltd (538965) — Share Price, Financials & Analysis"
symbol: "538965"
company: "Concord Drugs Ltd"
canonical: "https://tapetide.com/stocks/538965"
isin: "INE858L01010"
nse_symbol: "CONCORDDRUGSLTD"
bse_code: "538965"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 105.41
generated_at: "2026-09-13T18:37:25.988Z"
---

# Concord Drugs Ltd (538965)

Canonical page: https://tapetide.com/stocks/538965

## Company

- **NSE Symbol:** CONCORDDRUGSLTD
- **BSE Code:** 538965
- **ISIN:** INE858L01010
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2015-02-23
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** concorddrugs.in

## About

Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on 
approved formulations

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:50:43.232396Z.

- **Market Cap:** ₹105.41 Cr
- **Classification:** Microcap
- **P/E (reported):** 51.9
- **EPS (TTM):** ₹1.59
- **EPS (reported):** ₹0.01
- **Book Value:** ₹36.82
- **Price to Book:** 2.2
- **Dividend Yield:** 0%
- **ROE:** 0.99%
- **ROCE:** 6.98%
- **Debt to Equity:** 0.24
- **Revenue (yearly):** ₹78.74 Cr
- **Net Income:** ₹1.05 Cr
- **EBITDA:** ₹4.52 Cr
- **52-Week High:** ₹92.52
- **52-Week Low:** ₹61
- **RSI (14):** 58.92

## Tapetide Score

- **Score:** 44 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 25 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 51.21 | 9% |
| growth | 98.9 | 9% |
| momentum | 64.54 | 12% |
| ownership | 34.52 | 24% |
| quality | 42.89 | 22% |
| valuation | 24.63 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is expected to give good quarter

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -9.31%
- The company has delivered a poor sales growth of 8.13% over past five years.
- Company has a low return on equity of 1.63% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 370.89% | 124.1% | -21.02% |
| ebitda margin growth | 53.33% | -37.4% | -36.36% | -40.46% |
| net income growth | 120% | 250% | 5% | 21% |
| revenue growth | -44.85% | 73.82% | 14% | 8% |
| roce | 68.7% | 5.76% | -13.51% | 8.41% |
| roe | 109.43% | -29.29% | 1.83% | -68.17% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 7.38 | 12.62 | 14.47 | 6.35 | 11.84 | 10.77 | 7.96 | 13.38 | 10.07 | 16.84 | 35.56 | 20.9 |
| Expenses | 5.85 | 12.06 | 14.28 | 5.62 | 11.05 | 9.45 | 7.03 | 12.44 | 9.06 | 15.96 | 34.13 | 18.66 |
| Operating Profit | 1.53 | 0.56 | 0.19 | 0.73 | 0.79 | 1.32 | 0.93 | 0.94 | 1.01 | 0.88 | 1.43 | 2.24 |
| OPM % | 20.73 | 4.44 | 1.31 | 11.5 | 6.67 | 12.26 | 11.68 | 7.03 | 10.03 | 5.23 | 4.02 | 10.72 |
| Other Income | 0.01 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0.02 | 0 | 0 |
| Interest | 0.39 | 0.43 | 0.38 | 0.37 | 0.39 | 0.43 | 0.53 | 0.42 | 0.4 | 0.3 | 0.34 | 0.35 |
| Depreciation | 0.38 | 0.38 | 0.39 | 0.34 | 0.34 | 0.37 | 0.37 | 0.37 | 0.34 | 0.3 | 0.35 | 0.35 |
| Profit before tax | 0.77 | -0.25 | -0.58 | 0.02 | 0.07 | 0.52 | 0.03 | 0.15 | 0.27 | 0.3 | 0.74 | 1.54 |
| Tax % | 31.17 | -4 | -39.66 | 50 | 28.57 | 57.69 | 33.33 | 26.67 | 29.63 | 26.67 | 28.38 | 27.92 |
| Net Profit | 0.53 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 | 0.22 | 0.52 | 1.11 |
| EPS in Rs | 0.57 | -0.24 | -0.35 | 0.01 | 0.05 | 0.22 | 0.01 | 0.11 | 0.19 | 0.17 | 0.39 | 0.84 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 51.8 | 48.08 | 51.34 | 51.33 | 58.96 | 51.31 | 43.26 | 36.93 | 75.88 | 83.37 |
| Expenses | 47.02 | 44.43 | 48 | 48.11 | 53.37 | 46.97 | 39.58 | 33.16 | 71.61 | 77.81 |
| Operating Profit | 4.78 | 3.65 | 3.34 | 3.22 | 5.59 | 4.34 | 3.68 | 3.77 | 4.27 | 5.56 |
| OPM % | 9.23 | 7.59 | 6.51 | 6.27 | 9.48 | 8.46 | 8.51 | 10.21 | 5.63 | 6.67 |
| Other Income | 0.14 | 0.09 | 0.12 | 3.86 | 0.1 | 0.01 | 0.01 | 0.01 | 0 | 0.02 |
| Interest | 1.88 | 1.59 | 1.54 | 1.42 | 1.68 | 1.62 | 1.59 | 1.72 | 1.46 | 1.39 |
| Depreciation | 2.4 | 1.71 | 1.46 | 1.37 | 1.76 | 1.6 | 1.54 | 1.42 | 1.36 | 1.34 |
| Profit before tax | 0.64 | 0.44 | 0.46 | 4.29 | 2.25 | 1.13 | 0.56 | 0.64 | 1.45 | 2.85 |
| Tax % | 50 | 9.09 | 28.26 | 23.54 | 28.89 | 21.24 | 25 | 54.69 | 28.28 | — |
| Net Profit | 0.32 | 0.41 | 0.33 | 3.28 | 1.59 | 0.89 | 0.42 | 0.3 | 1.04 | 2.04 |
| EPS in Rs | 0.41 | 0.52 | 0.38 | 3.75 | 1.82 | 0.96 | 0.42 | 0.3 | 0.79 | 1.59 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 7.24 | 7.86 | 7.86 | 8.74 | 8.74 | 8.74 | 9.32 | 10 | 10 | 13.18 |
| Reserves | 11.75 | 11.46 | 15.29 | 14.74 | 18.02 | 19.62 | 22.38 | 23.82 | 24.11 | 35.34 |
| Borrowings | 15.43 | 13.62 | 9.83 | 9.57 | 12.97 | 16.43 | 15.63 | 14.93 | 16.91 | 11.61 |
| Other Liabilities | 21.11 | 73.48 | 49.79 | 24.96 | 10.15 | 11.66 | 9.31 | 7.55 | 7.56 | 11.72 |
| Total Liabilities | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.3 | 58.58 | 71.85 |
| Fixed Assets | 13.64 | 13.51 | 11.85 | 10.52 | 13.83 | 13.97 | 12.86 | 11.63 | 12.17 | 11.55 |
| CWIP | 0 | 0 | 0.29 | 1 | 0 | 0.55 | 0.92 | 1.63 | 2 | 2.43 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1.42 | 1.62 | 1.62 | 1.62 |
| Other Assets | 41.89 | 92.91 | 70.63 | 46.49 | 36.05 | 41.93 | 41.44 | 41.42 | 42.79 | 56.25 |
| Total Assets | 55.53 | 106.42 | 82.77 | 58.01 | 49.88 | 56.45 | 56.64 | 56.3 | 58.58 | 71.85 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 1.7 | 6.88 | 1.19 | 2.48 | 1.62 | 0.77 | 2.24 | 1.96 | 3.16 | -7.37 |
| Cash from Investing Activity | -1.04 | -2.21 | -0.34 | -0.84 | -3.67 | -2.44 | -2.27 | -1.21 | -2.32 | -1.13 |
| Cash from Financing Activity | -3.94 | -4.8 | -0.73 | -1.79 | 2.07 | 1.68 | 0.05 | -0.69 | -0.87 | 8.65 |
| Net Cash Flow | -3.28 | -0.13 | 0.12 | -0.15 | 0.02 | 0.01 | 0.03 | 0.06 | -0.02 | 0.16 |
| Free Cash Flow | 0.66 | 4.6 | 0.85 | 1.63 | -2.05 | -1.69 | 1.38 | 0.94 | 0.83 | -8.54 |
| CFO/OP | 38 | 152 | 36 | 78 | 65 | 26 | 60 | 59 | 89 | -163 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 99.46 | 501.49 | 367.66 | 180.94 | 147.41 | 141.52 | 116.31 | 117.87 | 125.22 | 135.31 |
| Inventory Days | 87.31 | 156.96 | 171.81 | 140.84 | 100.83 | 151.64 | 156.25 | 202.72 | 252.62 | 102.82 |
| Days Payable | 129.5 | 559.47 | 393.02 | 109.72 | 26.76 | 62.25 | 45.98 | 35.17 | 45.03 | 33.73 |
| Cash Conversion Cycle | 57.27 | 98.98 | 146.44 | 212.05 | 221.48 | 230.9 | 226.58 | 285.41 | 332.82 | 204.4 |
| Working Capital Days | 4 | 79.27 | 102.33 | 103.37 | 140.3 | 112.48 | 145.12 | 126.56 | 134.22 | 147.72 |
| ROCE % | 8.67 | 7.48 | 6.16 | 6.06 | 5.36 | 9.3 | 5.97 | 4.48 | 4.73 | 5.24 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 52.13% | 55.41% | 55.41% | 55.41% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 54.39% | 45.08% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 47.54% | 44.27% | 44.28% | 44.3% | 45.11% | 45.11% | 43.33% | 42.57% | 44.95% | 44.96% | 44.66% | 54.19% |
| Others | 0.33% | 0.32% | 0.31% | 0.29% | 0.5% | 0.5% | 2.28% | 3.04% | 0.66% | 0.65% | 0.94% | 0.73% |
| No. of Shareholders | 3957 | 4032 | 4734 | 4755 | 5073 | 5073 | 5252 | 5189 | 4718 | 4597 | 4464 | 4435 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 5 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 80.07 | Sell |
| EMA (10) | 79.58 | Buy |
| SMA (20) | 77.82 | Buy |
| EMA (20) | 78.22 | Buy |
| SMA (50) | 74.21 | Buy |
| EMA (50) | 76.43 | Buy |
| SMA (100) | 77.33 | Buy |
| EMA (100) | 76.28 | Buy |
| SMA (200) | 78.04 | Buy |
| EMA (200) | 73.15 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 55.54 | Neutral |
| MACD (12,26,9) | 1.77 | Sell |
| Stochastic (14,3,3) | 65.19 | Neutral |
| ADX (14) | 51.69 | Buy |
| Williams %R (14) | -41.95 | Neutral |
| ATR (14) | 4.56 | High Volatility |
| ROC (12) | -1.03 | Sell |
| Stoch RSI (14) | 16.75 | Buy |
| UO (7,14,28) | 46.92 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32000de3-cfcc-4817-8bec-a16ab8374221.pdf) |
| 2026-09-07 | [Board Meeting Outcome for Annual General Meeting To Be Held On 30.09.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f137c759-97c9-4c07-bb3b-8f8cd19fa15b.pdf) |
| 2026-09-07 | [31St Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18a03a24-bab1-40e2-87a5-7af3dc5e8e56.pdf) |
| 2026-09-07 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ef31d3b-c0b9-43bc-9fb0-96ca8e44aecb.pdf) |
| 2026-09-07 | [31St AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7965604-aea2-4ee2-ae4c-837e389407f1.pdf) |
| 2026-09-07 | [Intimation Of Record Date For 31St AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=91be7b2d-d566-45b5-b95b-4a4a62b84957.pdf) |
| 2026-09-07 | [Letter To Shareholders](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69b9d707-598b-41b5-8081-121e8b0209d5.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b5e5cf30-8748-4982-b33e-46c39ad76864.pdf) |
| 2026-08-10 | [Board Meeting Outcome for Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=532cf078-2569-4fd6-be41-92c0539aa673.pdf) |
| 2026-08-03 | [Board Meeting Intimation for Quarterly Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=03b9aed5-b7ae-46b5-95e6-516f316d9427.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-10 | [Financial Results For Quarter Ended 30 June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5bc3373e-0cf4-4343-839b-7ff28ea7cd30.pdf) |
| 2026-05-29 | [Financial Results For Year Ending 31St March2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f359d870-f774-4b31-bc12-2448fe70c901.pdf) |
| 2026-05-27 | [Financial Results For Period Ended 31St March2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e5aebf5a-681d-486e-9640-f4408c1cd951.pdf) |
| 2026-05-27 | [Financial Results For Period Ended 31St March2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d66ad573-e47c-4d86-a9b4-c8a76c041a33.pdf) |
| 2026-02-14 | [Financial Results For Quarter Ended 31St Dec2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8abd3739-a6d1-4621-bdbd-48b507efb182.pdf) |
| 2025-11-13 | [Financial Results For Quarter Ended 30 Sep 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=376c88ab-da13-4c4e-8d74-ebef56aa5032.pdf) |
| 2025-08-08 | [Financial Results For Quarter Ending 30 June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=37d46d19-5613-4ec7-a031-5f4320a512a5.pdf) |
| 2025-05-23 | [Financial Results For Quarter And Financial Year Ending March 31 St 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e2c57563-71ea-4170-9af9-2f76bee93dee.pdf) |
| 2025-01-11 | [Financial Results For 31St December2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d873928-4ee5-4fe9-a7ff-4921bdb2b4e9.pdf) |
| 2024-11-13 | [Financial Results For Q2 Ending Sep 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4dc0318f-ef92-46f0-91ec-a58f27e09830.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 6 May - Concord Drugs says it is not a Large Corporate as of March 31, 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 6 May - Concord Drugs says it is not a Large Corporate as of March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2a0e1448-212a-4b42-9080-3234750c3d6e.pdf) |
| 3 Mar 2017 - PAYMENT OF YEARLY INTEREST ON SBM BONDS: RECORD DATE - REGULATION 60 OF THE SEBI (LODR) REGULATIONS, 2015 | [Updates 3 Mar 2017 - PAYMENT OF YEARLY INTEREST ON SBM BONDS: RECORD DATE - REGULATION 60 OF THE SEBI (LODR) REGULATIONS, 2015](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/3/cfb7279a-960d-4974-8afc-80cb53bbb450.pdf) |
| 23 Feb 2017 - With reference to the earlier letter dated February 16, 2017 regarding Acquisition of State Bank of Mysore (SBM), by SBI, State Bank of Mysore has … | [Updates on Acquisition of State Bank of Mysore (SBM) by SBI 23 Feb 2017 - With reference to the earlier letter dated February 16, 2017 regarding Acquisition of State Bank of Mysore (SBM), by SBI, State Bank of Mysore has …](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/2/69B54BF3_FB9B_469F_AB5A_2E21C48FD205_190327.pdf) |
| 16 Feb - Corrigendum (16 Feb 2026): clarifies Labour Codes effective 21 Nov 2025; incremental liability accounted as immaterial. | [General Update 16 Feb - Corrigendum (16 Feb 2026): clarifies Labour Codes effective 21 Nov 2025; incremental liability accounted as immaterial.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fff987ac-1b73-4d0c-9a26-3e57acdac087.pdf) |
| 14 Feb - Approved standalone/consolidated results for quarter and nine months ended 31-Dec-2025; preferential issue Rs13,36,29,375; director ceased. | [Board Meeting Outcome for Out Come Of Board Meetings 14 Feb - Approved standalone/consolidated results for quarter and nine months ended 31-Dec-2025; preferential issue Rs13,36,29,375; director ceased.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ce4eb85-7029-4709-9794-1d1c9f6fc82e.pdf) |
| 14 Feb - 14 Feb 2026: Concord Drugs reconstituted Audit, Nomination & Remuneration, Stakeholders' committees; Kasu Sumeela appointed chair. | [Reconstitution Of Committees 14 Feb - 14 Feb 2026: Concord Drugs reconstituted Audit, Nomination & Remuneration, Stakeholders' committees; Kasu Sumeela appointed chair.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9f858d54-5bf2-4497-84e7-b025ea574569.pdf) |
| 10 Apr - Concord Drugs says Large Corporate framework not applicable for FY 2025–26. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 10 Apr - Concord Drugs says Large Corporate framework not applicable for FY 2025–26.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6d6e89e4-1f17-4c6a-88c9-e1752ed2f0d4.pdf) |
| 10 Apr - Concord Drugs says it is not a Large Corporate as of March 31, 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 10 Apr - Concord Drugs says it is not a Large Corporate as of March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f406f85f-4eb9-40cb-a4cd-77b811c74a93.pdf) |
| 10 Apr - Concord Drugs filed Regulation 74(5) certificate for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Apr - Concord Drugs filed Regulation 74(5) certificate for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fcb39c4f-d0aa-4fc2-b023-68b3b5ec0adc.pdf) |
| — | [Closure of Trading Window 27 Mar](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c74b2811-aaea-4e7a-bcba-2c8e25df6738.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cfc58de8-a9f0-411f-84b8-aac64ab50e4e.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4798f9ad-0159-4b18-9e26-2529d63cfafb.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3486daf6-a1ba-4827-bd06-58982cd101c6.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/538965/76732538965.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/538965/72081538965.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/538965/67953538965.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/538965/5389650319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/538965/5389650318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/538965/5389650317.pdf) |
| from bse | [Financial Year 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/532200/5322000316.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:37:25.988Z.